Rubius Therapeutics downgraded by Guggenheim
$RUBY
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Guggenheim downgraded Rubius Therapeutics from Buy to Neutral
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/13/2022 | Buy → Neutral | Guggenheim | |
| 2/25/2022 | $14.00 → $5.00 | Market Perform | SVB Leerink |
| 11/9/2021 | $20.00 → $14.00 | Market Perform | SVB Leerink |
| 10/19/2021 | $25.00 → $22.00 | Equal-Weight | Morgan Stanley |
4 - Rubius Therapeutics, Inc. (0001709401) (Issuer)
4 - Rubius Therapeutics, Inc. (0001709401) (Issuer)
4 - Rubius Therapeutics, Inc. (0001709401) (Issuer)